Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Last trade$2.67
Day change+$0.12 (+4.71%)
Day range$2.55 – $2.70
Volume159,909
Market cap$89M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$88.65M
Price / earnings
—
Price / book
6.13×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.95×
Profitability
Earnings per share
-$0.30
Return on assets
-68.87%
Return on equity
-71.74%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.54×
Quick ratio
8.54×
Cash ratio
0.8×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANIX, quarterly periods
Line item
Q3 FY2026 Jul 31, 2026
Q2 FY2026 Apr 30, 2026
Q1 FY2026 Jan 31, 2026
Q4 FY2025 Oct 31, 2025
Q3 FY2025 Jul 31, 2025
Q2 FY2025 Apr 30, 2025
Q1 FY2025 Jan 31, 2025
Q4 FY2024 Oct 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.41M
$1.39M
$1.61M
$1.73M
$1.38M
$1.68M
$1.83M
$1.69M
Research and development
$1.33M
$1.26M
$1.1M
$1.14M
$1.06M
$1.32M
$1.55M
$1.48M
Total operating expenses
$2.74M
$2.65M
$2.72M
$2.88M
$2.44M
$3M
$3.39M
$3.16M
Operating income
-$2.74M
-$2.65M
-$2.72M
-$2.88M
-$2.44M
-$3M
-$3.39M
-$3.16M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.63M
-$2.54M
-$2.59M
-$2.72M
-$2.28M
-$2.81M
-$3.21M
-$2.91M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.63M
-$2.54M
-$2.59M
-$2.72M
-$2.28M
-$2.81M
-$3.21M
-$2.91M
Net income attributable to common shareholders
-$2.61M
-$2.52M
-$2.57M
-$2.7M
-$2.26M
-$2.79M
-$3.18M
-$2.88M
EBITDA
-$2.74M
-$2.65M
-$2.72M
-$2.88M
-$2.44M
-$3M
-$3.39M
-$3.16M
Basic earnings per share
-$0.08
-$0.07
-$0.08
-$0.08
-$0.07
-$0.09
-$0.10
-$0.09
Diluted earnings per share
-$0.08
-$0.07
-$0.08
-$0.08
-$0.07
-$0.09
-$0.10
-$0.09
Recent news
Company coverage with links to the original publishers.
Anixa Biosciences announced that the Mexican Institute of Industrial Property has issued Patent Number 432748 covering the company's breast cancer vaccine technology. The patent extends intellectual property protection into 2040 and strengthens Anixa's global patent portfolio. The vaccine, developed with Cleveland Clinic, targets human α-lactalbumin and showed positive Phase 1 results with 74% of participants eliciting protocol-defined immune responses. The company is preparing for Phase 2 clinical trials.
Anixa Biosciences announced that South Korea's Ministry of Intellectual Property issued a Notice of Allowance for a patent covering the company's breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition of matter protection in South Korea and expands Anixa's global intellectual property portfolio. The company's Phase 1 clinical trial showed the vaccine was safe, well-tolerated, and generated immune responses in 74% of participants.
The cancer immunotherapy market is projected to reach $258.22 billion by 2031, driven by breakthrough treatments and FDA fast-track approvals. Multiple companies are developing innovative immunotherapies targeting various cancer types with promising clinical trial results.
Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, will present at the Sidoti Micro-Cap Virtual Conference on November 13-14, 2024. The company will provide updates on its breast cancer and ovarian cancer clinical trials, which have been producing positive results.
The FDA has approved Anixa Biosciences' application for an individual patient trial of its CAR-T therapy for recurrent ovarian cancer patients who have failed standard-of-care treatments. The therapy has shown promising early results, with one patient demonstrating a notable response despite initial tumor progression.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.